Arrakis Therapeutics
http://arrakistx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arrakis Therapeutics
Roche Partnering Finds Upfront Fee Relief In Current Market
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
Amgen, J&J, Takeda R&D Heads On The Era Of Human Data, Treating Disease Earlier
Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.
Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
J&J Jumps On RNA-Based Small Molecules Train In Pact With Remix
Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice